Literature DB >> 7649584

Effect of captopril and angiotensin II receptor blockade on pressure natriuresis in transgenic TGR(mRen-2)27 rats.

V Gross1, A Lippoldt, W Schneider, F C Luft.   

Abstract

The pressure-natriuresis curve of transgenic rats harboring an extra mouse renin gene [TGR(mRen-2)27] is shifted rightward compared with controls; however, whether intrarenal angiotensin II effects are responsible for the rightward shift is unknown. To clarify this issue we infused the converting enzyme inhibitor captopril or the angiotensin II receptor blocker CV 11974 into transgenic and normotensive Sprague-Dawley Hannover control rats. We eliminated any other neural or endocrine regulatory differences between transgenic and control rats by renal denervation and infusion of vasopressin, aldosterone, corticosterone, and norepinephrine in sufficient quantities to occupy all receptors. Sodium excretion increased from 3.4 +/- 1.2 to 10.1 +/- 0.5 mumol/min per gram kidney weight in transgenic rats when renal perfusion pressure was increased from 158 to 201 mm Hg. Captopril (4 mg/kg) and CV 11974 (0.1 mg/kg) shifted the pressure-natriuresis curve of transgenic rats leftward, so that sodium excretion was threefold higher at similar renal perfusion pressures (150 to 160 mm Hg). Similarly, fractional sodium and water excretion curves were shifted leftward, so that values for transgenic and control rats were no longer different. Over the pressure range, renal blood flow in transgenic rats ranged from 3.1 +/- 0.7 to 4.4 +/- 0.5 mL/min per gram kidney weight and increased (P < .05) with both captopril and CV 11974 to ranges from 4.8 +/- 0.9 to 6.8 +/- 0.6 or from 4.5 +/- 0.7 to 6.9 +/- 1.0 mL/min per gram kidney weight, respectively. Glomerular filtration rate in transgenic rats, on the other hand, was not increased. Transgenic kidneys showed severe hypertension-induced nephrosclerosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7649584     DOI: 10.1161/01.hyp.26.3.471

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

Review 1.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

2.  Recovery from renal ischemia-reperfusion injury is associated with altered renal hemodynamics, blunted pressure natriuresis, and sodium-sensitive hypertension.

Authors:  Kimberly R Pechman; Carmen De Miguel; Hayley Lund; Ellen C Leonard; David P Basile; David L Mattson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-08-26       Impact factor: 3.619

3.  Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade.

Authors:  M Böhm; A Lippoldt; W Wienen; D Ganten; M Bader
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

4.  Angiotensin-(1-7) is involved in the endothelium-dependent modulation of phenylephrine-induced contraction in the aorta of mRen-2 transgenic rats.

Authors:  Virgínia S Lemos; Steyner F Côrtes; Denise M R Silva; Maria J Campagnole-Santos; Robson A S Santos
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

5.  Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes.

Authors:  Kristin Kräker; Florian Herse; Michaela Golic; Nadine Reichhart; Sergio Crespo-Garcia; Olaf Strauß; Jana Grune; Ulrich Kintscher; Manal Ebrahim; Michael Bader; Natalia Alenina; Arnd Heuser; Friedrich C Luft; Dominik N Müller; Ralf Dechend; Nadine Haase
Journal:  Sci Rep       Date:  2020-08-20       Impact factor: 4.379

6.  Study on screening potential allergenic proteins from infant milk powders based on human mast cell membrane chromatography and histamine release assays.

Authors:  Ping Zhang; Yingdi Shi; Xiaoshuang He; Wei Sun; Yanni Lv; Xiaofang Hou
Journal:  J Pharm Anal       Date:  2018-08-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.